Molecular aging and p16INK4a in testicular cancer survivors

Molecular aging and p16INK4a in testicular cancer survivors

VJOncology

1 year
217 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Maria Teresa Bourlon, MD, MS, of Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, discusses the link between chemotherapy and premature ageing, via the biomarker p16INK4a, in testicular cancer survivors at the Genitourinary Cancers Symposium 2018, held in San Francisco, CA. Although testicular cancer patients can be cured successfully with chemotherapy, they still suffer from the long-term effects of the treatment. The results of Dr Bourlons research show an increased expression of the p16INK4a senescence protein in patients exposed to chemotherapy. p16INK4a has been found to inhibit CDK4/6 and promote p53 degradation, essentially causing premature senescence. Consequently, testicular cancer survivors may have an increased cancer risk, risk of infection and a weaker response to vaccinations, which is concerning for survivors.
Up Next Autoplay
Caris Life Sciences and Ambry Genetics Partner to Advance Cancer Care
Caris Life Sciences and Ambry Genetics Partner to Advance Cancer Care
Category: News
1 Views
Cancer-News 6 hours
Long-Term Results from Phase 3 ALTA-1L Trial
Long-Term Results from Phase 3 ALTA-1L Trial
Category: Non-Small Cell Lung Cancer
24 Views
Cancer-News 1 day
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Category: News
2 Views
Cancer-News 1 day
Treatment-Free Survival, With and Without Toxicity
Treatment-Free Survival, With and Without Toxicity
Category: Kidney Cancer
10 Views
kidneycancer 1 day
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Category: Kidney Cancer
1 Views
kidneycancer 1 day
What's To Come in Modern Imaging Technology
What's To Come in Modern Imaging Technology
Category: Kidney Cancer
3 Views
kidneycancer 2 days
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Category: Acute Myelogenous Leukemia
4 Views
Cancer-News 2 days
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
Category: Breast Cancer
6 Views
Cancer-News 2 days
Modern Imaging Technology
Modern Imaging Technology
Category: Kidney Cancer
9 Views
kidneycancer 3 days
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
Category: News
2 Views
Cancer-News 3 days